Drugs / HEC113995PA•H2O
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03943251 | Jul → Dec 2019 | — | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04591301 | Jul → Dec 2019 | major depressive disorder | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC113995 PA•H2O | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04591301 ↗ |
| Route | Oral | “Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.” NCT04591301 ↗ |